144243-24-3

Basic information

• Product Name: 1-BOC-3-AMINOPIPERIDINE
• Synonyms: DL-3-AMINO-1-N-BOC-PIPERIDINE;1-N-BOC-3-AMINOPIPERIDINE;1-PIPERIDINECARBOXYLIC ACID, 3-AMINO-, 1,1-DIMETHYLETHYL ESTER;(+/-)-1-BOC-3-AMINO-PIPERIDINE;1-BOC-3-AMINOPIPERIDINE;3-AMINOPIPERIDINE, N1-BOC PROTECTED;(+/-)-3-AMINO-1-BOC-PIPERIDINE;3-AMINO-1-TERTBUTOXYCARBONYL-PIPERIDINE
• CAS NO: 144243-24-3
• Molecular Formula: C₁₀H₂₀N₂O₂
• Molecular Weight: 200.28
• Product Categories: Amines;blocks;chiral
• Mol File: 144243-24-3.mol
• Article Data: 10

Chemical Properties

• Melting Point: 181-182℃
• Boiling Point: 277.3 °C at 760 mmHg
• Flash Point: 121.5 °C
• Appearance: Colorless to yellow/Liquid
• Density: 1.041 g/cm³
• Vapor Pressure: 0.00456mmHg at 25°C
• CAS DataBase Reference: 1-BOC-3-AMINOPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-3-AMINOPIPERIDINE(144243-24-3)
• EPA Substance Registry System: 1-BOC-3-AMINOPIPERIDINE(144243-24-3)

Safety Data

• Hazard Codes: Xn:Harmful
• Statements: R22:; R36/37/38:
• Safety Statements: S26:
• Hazardous Substances Data: 144243-24-3(Hazardous Substances Data)

Usage

General Description

1-BOC-3-aminopiperidine is a chemical compound that consists of a piperidine ring with an amino group at the 3-position, which is protected by a BOC (tert-butyloxycarbonyl) group. It is commonly used as an intermediate in organic synthesis, particularly in the pharmaceutical industry for the preparation of various drugs. The BOC protecting group can be removed under mild acidic conditions, allowing for further functionalization of the amino group. 1-BOC-3-aminopiperidine has potential applications in the synthesis of various pharmaceuticals and agrochemicals, making it an important building block in the field of medicinal chemistry and drug discovery.

InChI:InChI=1/C10H20N2O2/c1-10(2,3)14-9(13)12-6-4-5-8(11)7-12/h8H,4-7,11H2,1-3H3/p+1/t8-/m1/s1

Upstream product

• 54012-73-6 3-aminopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 189321-64-0 C₁₁H₁₈N₂O₃ 
• 129888-60-4 1-(tert-Butoxycarbonyl)-3-(methanesulfonyloxy)piperidine 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 6859-99-0 3-hydroxypiperazine 
• 129888-61-5 3-Azido-1-(tert-butoxycarbonyl)piperidine 

Downstream Products

• 816468-38-9 tert-butyl 3-[(4-methoxyphenyl)amino]piperidine-1-carboxylate 
• 183207-67-2 1-(tert-butoxycarbonyl)-3-(phenylamino)piperidine 
• 144243-36-7 3--N-methylamino>-1-methylpiperidine 
• 4606-66-0 3-(methylamino)-1-methylpiperidine 
• 144243-09-4 3--N-methylamino>-1-methylpiperidine 
• 247568-90-7 2-[1-(tert-butoxycarbonyl)piperidin-3-ylamino]-N-(3,4-dimethoxybenzyl)-5-nitrobenzamide 
• 247569-04-6 2-[1-(tert-butoxycarbonyl)piperidin-3-ylamino]-5-cyano-N-(3,4-dimethoxybenzyl)benzamide 
• 144243-26-5 1-(tert-butoxycarbonyl)-3-(1-pyrrolidinyl)piperidine 
• 247567-63-1 5-Cyano-N-(3,4-dimethoxybenzyl)-2-[1-(methanesulfonyl)piperidin-3-ylamino]benzamide 
• 247569-06-8 5-Cyano-N-(3,4-dimethoxybenzyl)-2-(1-formylpiperidin-3-ylamino)benzamide 
• 247569-05-7 5-cyano-N-(3,4-dimethoxybenzyl)-2-(piperidin-3-ylamino)benzamide 

Relevant articles and documents

Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity

With approximately 37 million people living with HIV worldwide and an estimated 2 million new infections reported each year, the need to derive novel strategies aimed at eradicating HIV-1 infection remains a critical worldwide challenge. One potential strategy would involve eliminating infected cells via antibody-dependent cellular cytotoxicity (ADCC). HIV-1 has evolved sophisticated mechanisms to conceal epitopes located in its envelope glycoprotein (Env) that are recognized by ADCC-mediating antibodies present in sera from HIV-1 infected individuals. Our aim is to circumvent this evasion via the development of small molecules that expose relevant anti-Env epitopes and sensitize HIV-1 infected cells to ADCC. Rapid elaboration of an initial screening hit using parallel synthesis and structure-based optimization has led to the development of potent small molecules that elicit this humoral response. Efforts to increase the ADCC activity of this class of small molecules with the aim of increasing their therapeutic potential was based on our recent cocrystal structures with gp120 core.

A modified Curtius reaction: an efficient and simple method for direct isolation of free amine

The Curtius rearrangement and related reactions are often used to convert carboxylic acids to the corresponding primary amines. However, this reaction often requires harsh conditions for hydrolysis of the isocyanate intermediates to amines, and can also be contaminated by the formation of corresponding ureas due to the reactive nature of the intermediates. We have discovered that by quenching the isocyanate intermediates with sodium trimethylsilanolate, the free amines can be isolated after aqueous workup. This mild and fast procedure provides free amines in one pot with good yields.

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.